sellWeak cluster of 4
Christopher Yea sold $35k of KALV
CHIEF DEVELOPMENT OFFICER at KalVista Pharmaceuticals, Inc.. 2,649 shares at an average of $13.19, traded Aug 18, 2025, filed Aug 19, 2025.
Warning score
21Value
$35k
2,649 shares
Holdings after
129,493
-2% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +6Trade size$35k at market
- 0Share of holdings soldSold 2.0% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-25-022306, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 17, 2025 | MOption exercise Common Stock | +4,203 | - | - | 132,142 | Aug 19, 2025 |
| Aug 18, 2025 | SOpen-market sale Common Stock | -2,649 | $13.19 | $35k | 129,493 | Aug 19, 2025 |
| Aug 17, 2025 | MOption exercise Restricted Stock Unitderivative | -1,773 | $0.00 | $0 | 5,322 | Aug 19, 2025 |
| Aug 17, 2025 | MOption exercise Restricted Stock Unitderivative | -2,430 | $0.00 | $0 | 2,431 | Aug 19, 2025 |
Related signals
Other insiders at KalVista Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 35Weak | KalVista Pharmaceuticals, Inc. | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | $120k 7,294 shares | -2% | |
| 22Weak | KalVista Pharmaceuticals, Inc. | Nicole Sweeny Chief Commercial Officer | $51k 3,813 shares | -9% | |
| 23Weak | KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $71k 5,296 shares | -4% | |
| 36Weak | KalVista Pharmaceuticals, Inc. | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | $147k 10,940 shares | -3% | |
| 22Weak | KalVista Pharmaceuticals, Inc. | Christopher Yea CHIEF DEVELOPMENT OFFICER | $58k 4,331 shares | -2% | |
| 39Weak | KalVista Pharmaceuticals, Inc. | Brian Piekos Chief Financial Officer | $60k 4,471 shares | -30% | |
| 21Weak | KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $45k 3,075 shares | -2% | |
| 33Weak | KalVista Pharmaceuticals, Inc. | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | $65k 4,466 shares | -1% | |
| 21Weak | KalVista Pharmaceuticals, Inc. | Christopher Yea CHIEF DEVELOPMENT OFFICER | $39k 2,683 shares | -2% | |
| 31Weak | KalVista Pharmaceuticals, Inc. | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | $38k 3,328 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.